Phase II study of antineoplastons A10 and AS2-1 in children with rhabdoid tumor of the central nervous system.

Trial Profile

Phase II study of antineoplastons A10 and AS2-1 in children with rhabdoid tumor of the central nervous system.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
  • Indications CNS cancer; Rhabdoid tumour
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2017 Status changed from active, no longer recruiting to discontinued.
    • 21 Jul 2009 Additional lead trial centre (NCI) identified as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top